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Herpes zoster is the consequence of the reactivation of
latent varicella-zoster infection. Immunosuppression may
be a predisposing factor for herpes zoster. We have retro-
spectively assessed the risk of herpes zoster, the risk factors
for its occurrence, and its evolution in a population of 209
consecutive liver transplant recipients. Herpes zoster
developed in 25 (12%) of patients. One-, 3-, 5-, and
10-year actuarial rates of herpes zoster were 3%, 10%,
14%, and 18%, respectively. In a case-control study,
patients developing herpes zoster were younger, received a
higher number of immunosuppressive drugs, and were
more frequently receiving mycophenolate mofetil or aza-
thioprine. In multivariate analysis, the only factor related
to herpes zoster occurrence was treatment with mycophe-
nolate mofetil or azathioprine. Eight patients (31%)
developed postherpetic neuralgia. In conclusion, herpes
zoster is a relateively common complication after liver
transplantation. It is related to immunosuppressive ther-
apy. Postherpetic neuralgia develops in one third of
patients with posttransplant herpes zoster. (Liver Transpl
2004;10:1140–1143.)
Latent varicella-zoster infection is almost universalin adult populations from Europe and North
America. Reactivation causes herpes zoster (HZ), which
appears as a painful cutaneous eruption with dermato-
mal distribution. The most frequent complication of
HZ is postherpetic neuralgia (PHN), whichmay persist
for months or even years.
The annual incidence of HZ in the general popula-
tion is 1.5 to 3.0 cases per 1,000 persons.1 Posttrans-
plant immunosuppressionmay increase this incidence.2
Several studies have evaluated the incidence of HZ
after bone marrow transplantion and in patients with
human immunodeficiency virus infection, but data on
liver transplant recipients are scarce.2,3 Therefore, we
have performed a retrospective study to investigate the
incidence, risk factors, and complications of HZ after
liver transplantation.
Patients and Methods
We have performed a retrospective analysis of our prospec-
tively collected database of all liver transplantations carried
out in our center between April 1990 and June 2002. All
patients were followed until December 2002. HZwas defined
as the appearance of a cutaneous vesicular eruption with a
dermatomal distribution. The location, distribution, exten-
sion, treatment, and complications of HZ were recorded.
PHNwas defined as pain in the area of the eruption persisting
for more than 30 days after the rash.4
Immunosuppressive therapy has been described prev-
iously.5 Calcineurin inhibitors (cyclosporine or tacrolimus),
azathioprine, and steroids were administered as primary
immunosuppression. Long-term monotherapy based on cal-
cineurin inhibitors was attempted. From 1996, calcineurin
inhibitors were partially or completely switched to mycophe-
nolate mofetil (MMF) in the case of renal insufficiency.6
Antiviral prophylaxis protocol included the administra-
tion of ganciclovir (5 mg/kg/day intravenously for 2 weeks) to
patients who were cytomegalovirus negative before transplan-
tation. Those patients with acute rejection who received ste-
roid boluses and/or OKT3 received prophylaxis with oral
acyclovir/ganciclovir for 4–8 weeks. Herpes simplex infec-
tion was treated with oral acyclovir for one week. Cytomega-
lovirus disease was treated with ganciclovir (5 mg/kg b.i.d.
intravenously for 2 weeks) followed by oral acyclovir for 2
months.
The actuarial incidence of HZ after liver transplantation
was obtained by the Kaplan-Meier method. To assess which
factors could predispose to HZ, a case-control study was per-
formed. Two controls were obtained for every case, namely
patients who had been transplanted immediately before and
after the case and were alive at the moment of the diagnosis of
HZ. Controls were not matched by age, sex, disease severity,
or cytomegalovirus status to make possible the study of these
variables as potential risk factors of HZ. The following data
were obtained from cases and controls: age; sex; cause of liver
transplantation; Child-Turcotte-Pugh status at transplanta-
tion; cytomegalovirus serology before transplantation; past
history of rejection; antiviral therapy; and immunosuppres-
sion (induction immunosuppression with cyclosporine,
cyclosporine microemulsion, or tacrolimus; current number
of immunosuppressive drugs; current and cumulative doses of
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prednisone; current use of MMF or azathioprine; and current
use of cyclosporine, tacrolimus, or none of them). The possi-
ble influence of renal insufficiency (defined as a creatinine
level equal or above 1.5mg/dL) and diabetes mellitus (defined
as the need for antidiabetic drugs) were also assessed at the
moment of diagnosis of HZ.
To compare both groups, chi-square and Mann-Whitney
U tests were used for categorical or continuous variables,
respectively. Multivariate analysis (logistic regression) was
performed with those variables with P  .1 in univariate
analysis.
Results
General characteristics of the patients are described in
Table 1. Twenty-five patients (12%) had HZ. The
median time of onset of HZ was 23 months (range, 10
days to 90 months) after transplantation. Actuarial 1-,
3-, 5-, 7-, and 10-year incidences of HZwere 3%, 10%,
14%, 17%, and 18%, respectively (Fig. 1). In 12 of the
cases (48%), HZ eruption was located in the thorax.
Other locations were neck and shoulder (3 cases), head
(3 cases), abdomen (2 cases), and leg (5 cases). All were
unilateral. In 5 cases (20%), more than one dermatome
was affected. In 4 cases (16%), the eruption recurred
after initial healing; two were early recurrences, and the
other 2 had HZ recurrence several years after the first
eruption. Eight patients (32%) had PHN. In 5 of these
patients, PHN resolved within 6 months, but the other
3 patients required pharmacological therapy for more
than 2 years. General characteristics ofHZ episodes and
antiviral therapy are shown in Table 2.
Regarding therapy, 1 patient did not receive antivi-
rals, 4 patients received intravenous acyclovir, 1 patient
received intravenous ganciclovir, 5 patients received
oral famciclovir, and 14 patients received oral acyclovir.
The duration of antiviral therapy was less than or equal
to 2 weeks in 19 patients. Four patients received anti-
viral treatment for 3–8 weeks, and 1 patient was treated
for 3 months. There was no relation between the devel-
opment of PHN and the antiviral drug used or the
duration of therapy.
General characteristics of cases and controls are
shown in Table 3. Patients with HZ were younger,
received a higher number of immunosuppressive drugs,
and were more frequently on treatment with azathio-
prine or MMF. In multivariate logistic regression anal-
ysis, the only factor related to HZ was treatment with
azathioprine or MMF (hazard ratio, 4.20; 95% confi-
dence interval, 1.48-11.91; P  .005).
Five of the 25 patients who had HZ had increases in
Table 1. General Characteristics of the Patients
No. of Patients
Age at transplantation (yr)* 55.5 (9.87)
Gender (male / female) 153 / 56
Cause of liver transplantation
Alcoholic cirrhosis 76
Hepatitis C virus cirrhosis 76
Hepatitis B virus cirrhosis 14
Primary biliary cirrhosis 10
Metabolic cirrhosis 13
Other causes 20
Hepatocellular carcinoma 67
Child-Turcotte-Pugh stage
(A / B / C)** 27 / 98 / 78
Acute rejection 54
Calcineurin inhibitor
Cyclosporine 95
Cyclosporine-Neoral 33
Tacrolimus 81
*Value expressed as mean (SD).
**Five patients without liver cirrhosis and one patient with
fulminant hepatic failure were not included.
Figure 1. Actuarial incidence of herpes zoster after liver
transplantation.
Table 2. General Characteristics of Herpes Zoster
Episodes, Therapy, and Evolution
Extension Number of Patients
One dermatome 20
More than one dermatome 5
Complications
Recurrences 4
Postherpetic neuralgia 8
Antiviral therapy (median duration)
None 1
Acyclovir (intravenous) 4 (1 week)
Acyclovir (oral) 14 (2 weeks)
Ganciclovir (intravenous) 1 (2 weeks)
Famciclovir 5 (one week)
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their immunosuppression in the 6 weeks preceeding
HZ. The causes of these increases were corneal trans-
plantation, retransplantation, treatment of recurrent
autoimmune hepatitis, and change of therapy due to
nephrotoxicity (association with MMF, and a switch
from cyclosporine to tacrolimus). Only one of the 50
controls had an increase in their immunosuppressive
therapy in the preceeding weeks.
Discussion
HZ is a consequence of the reactivation of latent infec-
tion by varicella-zoster virus. Our paper shows that HZ
is not an infrequent complication of liver transplanta-
tion. In fact, the incidence of HZ in our series is higher
than previously reported.2,3 This incidence is much
higher than the incidence of HZ in the general popula-
tion,7,8 and it seems to be comparable to the incidences
of HZ found in other solid-organ-transplant recipients2
and in patients with human immunodeficiency virus
infection9 butmuch lower than the incidence occurring
after bone marrow transplantation.10
As previously observed, the use of antiviral prophy-
laxis does not seem to prevent the development of HZ
after organ transplantation2 This finding in not surpris-
ing, as the onset of HZ following LT is relatively high,
and antiviral prophylaxis is administered in the first few
weeks after transplantation. In the same way, a past
history of rejection was not related to the development
of HZ, as most episodes of rejection happen in the early
posttransplant period. HZ seems to be more related to
maintenance immunosuppression, because it happened
amedian of 2 years after transplantation. In this setting,
an increase of immunosuppressionmay trigger the reac-
tivation of HZ. In our series, 20% of HZ happened
after recent increases of immunosuppression.
Development of HZ in liver transplant recipients is
related to immunosuppressive therapy. In their paper,
Gaurishankar et al. found that HZ was 4 times more
Table 3. Characteristics of Cases and Controls
Cases (N 25) Controls (N  50) P
Age (yr)* 55.7 (6.24) 57.5 (10.7) .076
Gender (male / female) 16 / 9 34 / 16 NS
CMV negative 0 3 NS
Indication of transplant NS
Alcoholic cirrhosis 8 14
HCV cirrhosis 8 21
HBV cirrhosis 2 3
Primary biliary cirrhosis 3 2
Metabolic cirrhosis 1 3
Hepatocellular carcinoma 7 20 NS
Child-Turcotte-Pugh (A / B / C) 2 / 11 / 11 11 / 23 / 18 NS
Initial immunosuppression NS
Cyclosporine 12 26
Cyclosporine Neoral 6 12
Tacrolimus 7 12
Actual immunosuppression NS
Cyclosporine 16 31
Tacrolimus 9 18
Number of immunosuppressive drugs* 2.24 (.18) 1.76 (.12) .017
AZA or MMF 18 19 .007
Previous rejection 10 18 NS
Antiviral therapy NS
No 11 27
Less than 4 weeks 6 11
More than 4 weeks 7 10
Diabetes mellitus 3 10 NS
Renal insufficiency 10 12 NS
Abbreviations: NS, not significant; AZA, azathioprine; MMF, mycophenolate mofetil; CMV, cytomegalovirus; HCV, hepatitis C virus;
HBV, hepatitis B virus.
*Values expressed as mean (SD).
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frequent in patients receiving MMF than in patients
receiving azathioprine.2 In our series, therapy with aza-
thioprine or MMF was the only factor independently
related to the occurrence of HZ.
Despite an older age is a predisposing factor for HZ
in the general population, in our series cases were not
older than controls. In the posttransplant setting, the
weight of immunosuppression as a predisposing factor
for HZ may mask the potential effect of age. Further-
more, as younger patients have a higher risk of rejec-
tion11 they usually require a more powerful immuno-
suppression. In our series, most patients received
antiviral therapy with oral acyclovir or famciclovir. This
therapy was effective, but 2 patients had early recur-
rence ofHZ, shortly after primary healing.One of them
did well with another 1-week course of oral acyclovir.
The other received antiviral therapy for 3 months.
One of the most feared complications of HZ is PHN.
In this series, one third of the patients had this complica-
tion, and for some of the patients with PHN, pain per-
sisted for years. This proportion is relatively high, but it is
comparable to the proportion of PHN in immunocompe-
tent patients older than 60 years.4 Fortunately, none of the
patients in this series had any other more severe complica-
tion ofHZ, such as retinitis, visceral involvement, or other
neurological complications.12
In conclusion, HZ is a frequent complication after
liver transplantation. Its evolution is usually satisfactory
with oral therapy, but PHN is a frequent complication.
Patients receiving more intensive immunosuppression
have a greater risk of developing HZ.
References
1. Gnann JW,Whitley RJ. Herpes zoster. N Engl JMed 2002;347:
340–346.
2. Gourishankar S,McDermid JC, Jhangri GS, Preiksaitis JK. Her-
pes zoster infection following solid organ transplantation: inci-
dence, risk factors and outcomes in the current immunosuppres-
sive era. Am J Transplant 2004;4:108–115.
3. Gnann JW. Other herpesviruses: Herpes simplex virus, varicella-
zoster virus, human herpes types 6, 7, and 8. In: Transplant
Infections, 1st edition. Philadelphia, PA: Lippincott-Raven;
1998:265–286.
4. Kost RG, Strauss SE. Postherpetic neuralgia: Pathogenesis, treat-
ment and prevention. N Engl J Med 1996;335:32–42.
5. Herrero JI, Lucena JF, Quiroga J, Sangro B, Pardo F, Rotellar F,
et al. Liver transplant recipients older than 60 years have lower
survival and higher incidence of malignancy. Am J Transplant
2003;3:1407–1412.
6. Herrero JI, Quiroga J, Sangro B, Girala M, Gomez-Manero N,
Pardo F, et al. Conversion of liver transplant recipients on cyclo-
sporine with renal impairment to mycophenolate mofetil. Liver
Transpl Surg 1999;5:414–420.7. Donahue JG, Choo PW,
Manson JE, Platt R. The incidence of herpes zoster. Arch Intern
Med 1005;155:1605–1609.
8. Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry
HO. Population-based study of herpes-zoster and its sequelae.
Medicine (Baltimore) 1982;61:310–316.
9. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O’Malley PM,
Underwood R, Holmber SD. Herpes zoster and human immu-
nodeficiency virus infection. J Infect Dis 1992;166:1153–1156.
10. Gomez-Manero N, Herrero JI, Quiroga J, Sangro B, Pardo F,
Cienfuegos JA, Prieto J. Prognostic model for early acute rejec-
tion after liver transplantation. Liver Transpl 2001;7:246–254.
11. Gilden DH, Kleinschmidt-DeMaster BK, LaGuardia JJ,
Mahalingam R, Cohrs RJ. Neurologic complications of the reac-
tivation of varicella-zoster virus. N Engl J Med 2000;342:635–
645.
1143Herpes Zoster After Liver Transplantation
